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The role of diabetes in the pathogenesis of cardiovascular disease was unclear until 1979 when Kannel and
McGee used data from the Framingham Heart Study to identify diabetes as a major cardiovascular risk
factor. It was among the ﬁrst studies to demonstrate the higher risk of cardiovascular disease in women
with diabetes than in men with diabetes. Since then, multiple studies have been done to recognize and
curtail cardiovascular risk factors such as smoking, obesity, hypertension, hyperlipidemia, and insulin
resistance. This review will examine the contribution of the Kannel and McGee paper and subsequent
studies in deﬁning the contribution of several risk factors on cardiovascular disease.From the *Department of
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j.gheart.2012.12.008In 1949, it was noted that “the proper control of dia-
betes is obviously desirable even though there is uncertainty
as to whether coronary atherosclerosis is more frequent or
severe in the uncontrolled diabetic” [1]. The role of dia-
betes in cardiovascular disease (CVD) had been uncertain
until the prominent paper published by Kannel and McGee
in 1979 [2] identiﬁed it as a major risk factor based on
evidence from the Framingham Heart Study (FHS), the
seminal prospective study of CVD and its determinants.
This study provided an update to the FHS, using data that
had been collected for 20 years. The results, hence,
changed the way healthcare providers thought about dia-
betes and paved the way for its establishment as a major
cardiovascular risk factor. The Kannel and McGee paper is
brieﬂy discussed here with its major implications and
contributions to subsequent studies.
DETERMINANTS OF CVD FROM FHS
Kannel and McGee studied the Framingham cohort of men
and women 45 to 74 years of age at the time of the study
who had been followed biennially over a 20-year period. At
each biennial examination, participants diagnosed with the
deﬁned cardiovascular endpoints were identiﬁed. The
diagnosis of diabetes in this study was made based on either
a history of treatment with oral hypoglycemic agents or
insulin, or a random blood glucose level>150 on 2 separate
occasions; participants with these characteristics and an
abnormal glucose tolerance test were classiﬁed as having
diabetes. Selection was performed at each biennial exami-
nation based on age, status of diabetes, and other charac-
teristics of interest. At each subsequent biennial
examination, incidence of cardiovascular events was docu-
mented and the participants were then reclassiﬁed.
The investigators looked at 3 variables to determine
the effect of diabetes on the incidence of CVD: 1) absolute
rate at which CVD develops; 2) relative risk of developing
CVD; and 3) the attributable fraction, which is deﬁned as
the percent decrease in the incidence of disease that wouldGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 43-48occur if the risk factor were not present. Attributable
fraction minimizes the effect of rare conditions and,
therefore, identiﬁes risk factors for a particular disease that,
if curtailed, would be of signiﬁcant importance to the
population as a whole.
In the 20years of follow-up, therewere 957 cases ofCVD,
which included 732 cases of coronary artery disease (CAD),
138 strokes, 179 cases of intermittent claudication, and 219
cases of congestive heart failure (CHF). Looking at the results
comprehensively, men had a higher incidence of CVD than
didwomen. Furthermore, comparing the various risk factors,
diabetes and left ventricular hypertrophy based on electro-
cardiographic abnormalities were the least prevalent risk
factors when compared with smoking and hypertension.
Diabetes was then individually examined as a risk factor
for CVD. First, the relative risk of CVD was examined for
those with and without diabetes. Diabetes seemed to double
the risk of total CVD in men and triple it in women (Fig. 1).
Furthermore, after age-adjustment, relative risks were
higher for women than for men for every endpoint that the
investigators had considered in the study (CHF, intermittent
claudication, stroke, coronary heart disease, CVD, and CVD
deaths) (Fig. 1). More signiﬁcantly, the risks of CHF and of
CVD death were doubled for men and tripled for women
with diabetes even after adjustment (Fig. 1) [2].
When comparing sex differences, the incidence was
greater for men without diabetes than for women without
diabetes for every endpoint considered. However, women
with diabetes had a higher incidence than did men without
diabetes, and for CHF and stroke, women with diabetes
had a higher incidence than did men with diabetes [2].STUDYING DIABETES AS A RISK FACTOR FOR CVD:
USING DATA FROM THE FHS
Trends in diabetes
Multiple studies have followed the original Kannel and
McGee publication in 1979 to better deﬁne the role of43
FIGURE 1. Adjusted and unadjusted relative risks of speciﬁed events in 2 years for diabetics versus nondiabetics ages
45 to 74 years at time of examination. Reprinted, with permission, from Kannel and McGee [2]. ECG, electrocardio-
gram; LVH, left ventricular hypertrophy.
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contribution of diabetes is especially important because the
deﬁnition of diabetes has changed since the publication of
the original study, and the prevalence of diabetes has
increased dramatically [3]. In 2006, Fox et al. [4] showed
that the incidence of diabetes almost doubled between
1970 and 1990. Furthermore, even though there has been
a 50% reduction in the rate of CVD among participants
with diabetes from the FHS, the relative risk of diabetes as
a risk factor for CVD has been unchanged [5].
Additionally, since the Kannel and McGee paper other
studies have also looked at how the attributable risk has
changed over time for diabetes andCVD. The attributable risk
for diabetes as a risk factor for CVD has increased from 5.4%
between 1952 and 1974 to 8.7%between 1975 and 1998 [6].
The importance of this ﬁnding is highlighted when other
factors are observed as well; the attributable risk for other
factors has either decreased or remained stable (Fig. 2) [6].
Examination of these ﬁndings underscores the large
contribution of diabetes to CVD. Using data from the FHS,
Preis et al. [7] examined 4,195 participants at 50 years of
age and 3,495 participants at 60 years of age from 1970 to2005. Participants with diabetes, as compared to those
without diabetes, had a greater increase in body mass
index, a larger decrease in low-density lipoprotein, and
a decline in their systolic blood pressure [7]. However,
only 14% of participants with diabetes from the FHS had
their hypertension optimally controlled and 23.1% had
low-density lipoprotein within goal range for those with
diabetes [7]. These ﬁndings highlight the fact that
improvements in risk factor control for CVD that have
occurred in the last 3 decades are measureable but not
sufﬁcient to meet the goals set for participants with dia-
betes, therefore leading to a persistently elevated CVD risk
in this population.
Diabetes duration was also suggested as an important
factor in assessing risk for CVD. In 2004, Fox et al. [8]
looked at the effect that the duration of diabetes had on
CVD by using data from the original FHS cohort as well as
their offspring. The results showed that after adjusting for
age, CAD risk factors, and sex for every 10 years of dia-
betes, the risk of CAD event was 1.38 higher and the risk
of CAD-related death was 1.86 higher. This study was
important as it showed that CAD and CAD-related deathsGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 43-48
FIGURE 2. Age- and sex-adjusted population attributable risk for diabetes as compared with other standard
cardiovascular disease risk factors from the Framingham Heart Study. Reprinted, with permission, from Fox et al. [6].
CI, conﬁdence interval; HTN, hypertension.
gREVIEWjare directly related to the duration of diabetes [8]. This
study has important implications for primary prevention of
diabetes mellitus to delay or stop its onset and, in effect,
decrease CAD and CAD-related deaths.Cardiovascular mortality related to diabetes and
diabetes as a CAD equivalent
There have been multiple studies looking at the effect of
diabetes on cardiovascular mortality since the Kannel and
McGee study, which was able to show an increase in
mortality from CVD in participants with diabetes versus
those without diabetes. With more emphasis on preventive
medicine and better understanding of treatment of dia-
betes, there has been a decline in cardiovascular mortality
in patients with diabetes over the last few decades [9].
However, diabetes continues to be a strong risk factor for
CVD and with a 4-fold increase in mortality [6,10]. In
2004, Fox et al. [5] were able to show that there had been
a decrease in the rate of CVD both among those with and
without diabetes, and multiple other studies have shown
decreased mortality rates in both subgroups as well
[11,12]. Upon further exploration, the NHANES (National
Health and Nutrition Examination Survey) study found
that this decrease in mortality is mostly for men and does
not apply to women; there was, in fact, an increase in
mortality in women with diabetes [10]. All of these studies
presented conﬂicting evidence about changes in cardio-
vascular mortality, especially among the fraction of the
population with diabetes.
Preis et al. [7] were able to use data from the FHS from
1950 to 2005 to look at trends in all-cause and CVD
mortality in both men and women with and withoutGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 43-48diabetes. In contrast to the NHANES study, this study
showed a decline in all-cause and CVD mortality in both
men and women with diabetes. It also showed that men
and women with diabetes continued to be at higher risk of
CVD and all-cause mortality than those without diabetes
[7]. These ﬁndings have been supported and replicated in
other studies as well, showing a decrease in CVD mortality
in men and women with diabetes (Fig. 3) [7,12].
In 1998, Haffner et al. [13] were able to show that
diabetic patients without a prior myocardial infarction were
at a similar risk of developing myocardial infarction as were
those patients without diabetes and a history of myocardial
infarction [13]. Furthermore, in 2005, Whiteley et al. [14]
were able to show that middle-aged men and women with
diabetes but no CAD were at a lifetime vascular risk as high
as individuals with CAD but no diabetes were. However,
one of the most important studies identifying diabetes as
a CAD risk-equivalent was conducted by Schramm et al.
[15] in 3.3 million Danish residents, which showed that
patients with diabetes had a CVD risk comparable to those
individuals without diabetes. All of these studies high-
lighted the notion that diabetes should be considered
a CAD risk-equivalent.FRAMINGHAM OFFSPRING STUDY: RISK FACTORS
AND SURROGATE MARKERS FOR CVD
The Framingham Offspring Study (FOS) have also
provided further insight into insulin resistance as well as
diabetes as CVD risk factors. In 2002, Meigs et al. [16]
examined 3,370 subjects from the Framingham offspring
cohort and found post-challenge hyperglycemia as an
independent risk factor for CVD. This is especially45
AB
FIGURE 3. Age-adjusted (A) cardiovascular disease (CVD) and (B) all-cause mortality rates among participants with
and without diabetes, by sex and time. Reprinted, with permission, from Preis et al. [7].
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46important because fasting hyperglycemia has largely
replaced post-challenge hyperglycemia for diagnosing dia-
betes [17] and several studies have shown that fasting
hyperglycemia overlooks a signiﬁcant number of people at
risk for CVD who are identiﬁed using post-challenge
hyperglycemia [18,19].
Additionally, other FOS have used data to identify
surrogate markers for CVD in diabetics. Meigs et al. [20]
found that participants with diabetes had more coronary
artery calciﬁcation than those without diabetes, indicating
a higher burden of subclinical CVD not detected by
conventional testing. Similarly, other studies have shown
that elevated levels of C-reactive protein [21] and homo-
cysteine [16] are both associated with insulin resistance
and an increased risk of CVD.
GLOBAL IMPACT AND OTHER NON-FRAMINGHAM
STUDIES FOLLOWING THE KANNEL AND MCGEE
ARTICLE
Other studies conducted throughout the world built on
the foundation created by the FHS. The INTERHEART(A Study of Risk Factors for First Myocardial Infarction in
52 Countries and Over 27,000 Subjects) collected data
from 52 countries and found diabetes, abdominal obesity,
and hypertension to be strong risk factors for CAD after
smoking and abnormal lipids [22]. Similarly, Stengård
et al. [23] were able to show in the Finnish cohort of the
Seven Countries Study the role of diabetes in CAD. Hence,
the FHS set a precedence for well-designed longitudinal
studies around the world that helped our understanding
about the role of diabetes in CVD.
Studying global trends in diabetes, Whiting et al. [24]
were able to show that the highest diabetes prevalence for
2011 was for Middle East and North Africa; however, the
largest increase in adult diabetes by 2030 would be for
African nations. Furthermore, even though China and
India already have the highest number of people ages 20 to
79 with diabetes (90 and 61.3 million people, respec-
tively), 48% of the predicted increase of 186 million in
people with diabetes from 2011 to 2030 would be in these
2 populous nations [24]. Due to the increased risk of CVD
in patients with diabetes as seen in the FHS and otherGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 43-48
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subsequent studies, these statistics present a difﬁcult
challenge to health care and an enormous public health
dilemma that needs to be more closely monitored and
intercepted.
Since the Kannel and McGee paper, many studies
have replicated the increased risk of CAD and CAD
mortality in women with diabetes compared with men
with diabetes [25,26]. The Strong Heart Study showed
a larger impact of diabetes on CV risk factors in women,
but the reason for an increased risk in women is still not
completely understood [27]. Whereas these studies have
replicated most of the ﬁndings from the Kannel and
McGee paper, our understanding of pathogenesis of CVD
due to diabetes has improved signiﬁcantly, with hyper-
insulinemia, insulin resistance [28], and hypercoagula-
bility [29] playing a role in the excess CVD risk in patients
with diabetes.IMPACT OF FHS ON RISK ASSESSMENT,
GUIDELINES, AND CLINICAL PRACTICE
Since the inception of the FHS, researchers have tried to
devise a score that would help predict the risk of devel-
oping CAD based on risk factors. Truett et al. [30] were the
ﬁrst to use data from the FHS to develop a risk score for
men and women based on 7 risk factors: age, systolic
blood pressure, relative weight, hemoglobin, cigarette
smoking, and electrocardiographic evidence of left
ventricular hypertrophy. Over time, hemoglobin and left
ventricular hypertrophy were removed [31]; glucose
intolerance was added; and the American Heart Associa-
tion published a book of risk tables in 1973 [32]. Even-
tually, in 1991, a point scoring system was developed to
help clinicians risk-stratify patients, [33] and, in 2008,
a tool was developed for primary care physicians [34]. Data
from the FHS, therefore, were crucial in devising the
Framingham Risk Score to determine the 10-year risk of
developing CAD [34].
Even though our understanding of the pathogenesis of
CVD in patients with diabetes has improved, the incidence
and prevalence of diabetes has increased signiﬁcantly as
well. Shaw et al. [35] showed that the burden of diabetes
will increase signiﬁcantly from 2010 to 2030, with a 69%
increase in adult diabetes in developing countries, and
a 20% increase in developed countries; the associated
population increase is expected to be 36% and 2%,
respectively. Based on these ﬁgures, the diabetes burden
will lead to increasing morbidity, mortality, stress on
healthcare providers, and healthcare-associated costs. A
joint statement by the American Heart Association and
American Diabetes Association in 2007 said that a multi-
faceted approach including risk factor control as well as
aggressive lifestyle changes must be employed to prevent
the development of diabetes and its complications, most
importantly CVD [36]. Using the available data, more
individualized plans of action with multifactorial inter-
ventions need to be devised to reduce the incidence ofGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 43-48CVD as well as CVD-related mortality in patients with
diabetes.
CONCLUSIONS
The Kannel and McGee study was among the ﬁrst to
describe diabetes mellitus as a signiﬁcant risk factor for
cardiovascular disease, especially among women. Multiple
studies have subsequently examined the role of diabetes as
well as other coexisting risk factors and comorbidities that
increase the risk of CVD. Current guidelines address target
levels of coexisting risk factors in those with diabetes.
However, recent studies suggest that there may be different
levels of recommended glycemic controls depending on
either the duration of diabetes or the presence of comor-
bidities such as existing CVD. Noninvasive screening tech-
niques such as coronary artery calcium score are also being
increasingly used in clinical practice to risk-stratify indi-
viduals who need more expensive and invasive screening
modalities. The Kannel and McGee paper was seminal in
identifying an important risk factor for CVD, and the ﬁnd-
ings have been paramount in guiding research that followed.
Future research needs to be done to look at surrogate
markers for CVD and to see how successful individualiza-
tion of treatment protocols is in preventing CVD.
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